Latest News
- February 5, 2009
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2009
- February 4, 2009
- KYORIN Updates Credit Rating from R&I
- January 29, 2009
- Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008
- December 24, 2008
- Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
- October 1, 2008
- Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
- September 30, 2008
- Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
- April 18, 2008
- Launch of KIPRES Tablets 5mg
- February 21, 2008
- Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
- January 30, 2008
- Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
- January 25, 2008
- KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis
- December 26, 2007
- KYORIN Obtains Credit Rating from R&I
- October 12, 2007
- Discontinuation of Cooperation on Baynas Marketing for Treatment of Allergic Rhinitis by Kyorin Pharmaceutical Co.,Ltd. and Bayer Yakuhin,Ltd.
- October 2, 2007
- Launch of "KIPRES" Oral Granules 4mg
- September 26, 2007
- Merger between Kyorin Phamaceutical Co.,Ltd. and Nisshin Kyorin Pharmaceutical Co.,Ltd.
- July 31, 2007
- Marketing Approval for "KIPRES" Oral Granules 4mg
- March 10, 2006
- On the Transition to a Holding - Company Structure
- Previous Page
- 5
- 6
- 7